Positron emission tomography/computed tomography in B-cell non-Hodgkin’s lymphoma at Hanoi Oncology Hospital

Abstract

This study aimed to review ¹⁸fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography (¹⁸FDG PET/CT) imaging characteristics of B-cell non-Hodgkin’s lymphoma (NHL) at Hanoi Oncology Hospital. PET/CT helps accurately assess the NHL stage compared with other diagnostic imaging methods, such as CT and magnetic resonance imaging. In this retrospective descriptive study, 86 newly diagnosed B-cell NHL cases were histopathologically and immunohistochemically examined at Hanoi Oncology Hospital between January 2018 and December 2022. Patients underwent ¹⁸FDG PET/CT for pretreatment staging. The stages before and after PET/CT were evaluated and compared. Before PET/CT, 26 (30.2%), 29 (33.7%), 15 (17.5%), and 16 (18.6%) patients were in stages I, II, III, and IV, respectively. After PET/CT, the rates of Stage I, II, III, and IV cases were 22.1%, 26.8%, 20.9%, and 30.2%, respectively. PET/CT results increased the stage in 21/86 patients (24.4%). The proportion of patients with advanced stages after PET/CT in the rapidly progressing histopathology group was higher (25%) than the slowly progressing histopathology group (21.4%), and the difference was not significant. Therefore, PET/CT is critical for accurately determining the disease stage of B-cell NHL, thereby helping to detect additional lesions missed by conventional imaging diagnostic tools.

Keywords

B-cell non-Hodgkin’s lymphoma / ¹⁸FDG PET/CT / Pre-PET/CT stage / Post-PET/CT stage

Acknowledgments

The authors thank the patients and the colleagues who made this work possible.

Funding

None.

Conflict of interest

Phuong Pham Cam is an Editorial Board Member of this journal but was not in any way involved in the editorial and peer-review process conducted for this paper, directly or indirectly. Separately, other authors declared that they have no known competing financial interests or personal relationships that could have influenced the work reported in this paper.

Author contributions

Conceptualization: Phuong Pham Cam, Thai Pham Van

Investigation: Thang Nguyen Van, Nien Vu Thi, Phuong Pham Cam, Thai Pham Van

Methodology: Thang Nguyen Van, Thai Pham Van

Writing-original draft: Thang Nguyen Van, Nien Vu Thi, Phuong Pham Cam

Writing-review & editing: Phuong Pham Cam, Thai Pham Van

Ethics approval and consent to participate

This study was approved by Hanoi Medical University (certificate of approval No. 4670/QĐ-ĐHYHN). This is a retrospective, non-interventional study thus ethics approval is not required.

Consent for publication

Informed consent was obtained from the patients to publish their data.

Availability of data

Not applicable.

References

[1] Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74(3):229-263. doi: 10.3322/caac.21834

[2] Fueger BJ, Yeom K, Czernin J, et al. Comparison of CT, PET, and PET/CT for Staging of patients with indolent non- Hodgkin’s lymphoma. Mol Imaging Biol. 2009; 11(4):269-274. doi: 10.1007/s11307-009-0200-9

[3] Pham VT, Thieu TH, Mai TK, et al. Evaluate the role of 18FFDG PET/CT in diagnosing the stage of non-Hodgkin’s lymphoma. Vietnam J Oncol. 2018;5:75-79.

[4] Nguyen HT, Nguyen KL, Nguyen HN, et al. The role of 18FDG PET/CT in assessing stage and response to treatment of malignant non-Hodgkin’s lymphoma. J Milit Med Pharm. 2022;6:107-117.

[5] Mai HS, Le NH. FDG PET/CT in stage assessment Stage and response to treatment of extranodal non-Hodgkin lymphoma. Vietnam J Radiol. 2022; 25:58-64. doi: 10.55046/vjrnm.25.642.2016

[6] Kasireddy S, Nirmal S, Kathal R, et al. A systematic review of the role of PET-CT imaging in the assessment of treatment response and its predictive value for survival outcomes in adult patients with newly diagnosed Hodgkin lymphoma: A comparison with conventional imaging techniques. Research Square [Preprint]; 2024. doi: 10.21203/rs.3.rs-3837903/v1

[7] Metser U, Prica A, Hodgson DC, et al. Effect of PET/CT on the management and outcomes of participants with Hodgkin and aggressive non-Hodgkin lymphoma: A multicenter registry. Radiology. 2019; 290(2):488-495. doi: 10.1148/radiol.2018181519

[8] Raanani P, Shasha Y, Perry C, et al. Is CT scan still necessary for staging in Hodgkin and non-Hodgkin lymphoma patients in the PET/CT era? Ann Oncol. 2006; 17(1):117-122. doi: 10.1093/annonc/mdj024

[9] Omar NN, Alotaify LM, Abolela MS. PET/CT in initial staging and therapy response assessment of lymphoma. Egypt J Radiol Nucl Med. 2016; 47(4):1639-1647. doi: 10.1016/j.ejrnm.2016.07.009

[10] Barrington SF, Kirkwood AA, Franceschetto A, et al. PET-CT for staging and early response: Results from the response-adapted therapy in advanced hodgkin lymphoma study. Blood. 2016; 127(12):1531-1538. doi: 10.1182/blood-2015-11-679407

[11] Adams HJA, Kwee TC, Keizer B, et al. FDG PET/CT for the detection of bone marrow involvement in diffuse large B-cell lymphoma: Systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2014; 41(3):565-574. doi: 10.1007/s00259-013-2623-4

[12] Li Z, Li C, Chen B, et al. FDG-PET/CT versus bone marrow biopsy in bone marrow involvement in newly diagnosed paediatric lymphoma: A systematic review and metaanalysis. J Orthop Surg Res. 2021; 16(1):482. doi: 10.1186/s13018-021-02521-3

[13] Berthet L, Cochet A, Kanoun S, et al. In newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET/CT provides better diagnostic performance and prognostic stratification than does biopsy. J Nucl Med. 2013; 54(8):1244-1250. doi: 10.2967/jnumed.112.114710

[14] Wang D, Huo Y, Chen S, et al. Whole-body MRI versus 18F-FDG PET/CT for pretherapeutic assessment and staging of lymphoma: meta-analysis. Onco Targets Ther. 2018; 11:3597-3608. doi: 10.2147/OTT.S148189

[15] Maccioni F, Alfieri G, Assanto GM, et al. Whole body MRI with diffusion weighted imaging versus 18f-fluorodeoxyglucose-PET/CT in the staging of lymphomas. Radiol Med. 2023; 128(5):556-564. doi: 10.1007/s11547-023-01622-9